Do you have an experience with lupus to share?
Learn more about our lupus registry, RAY, and how you can be a part of lupus research.
Can mesenchymal stromal cell therapy treat lupus?
Mesenchymal stromal cell (MSC) therapy is a promising frontier in lupus research, especially for people whose lupus doesn’t respond to other treatments (called refractory lupus). MSCs are cells derived from sources such as umbilical cord tissue that are being studied for their potential to help regulate immune responses.
MSC infusions do not require immune matching between healthy donor and lupus patient recipient, and no conditioning therapy is needed before treatment. Prior studies have reported few if any side effects, making MSCs a potentially safe and effective alternative treatment for people with lupus.
The Lupus Foundation of America was the first lupus organization in the U.S. to support MSC research. In partnership with the National Institute of Allergy and Infectious Diseases, the Lupus Foundation of America committed nearly $4 million over five years to co-fund a major study of adult MSCs as a new treatment for moderate to severe lupus.
The MSCs study is the first step in determining whether MSC therapy is safe and effective for people with lupus who do not benefit from currently available treatments. The study will determine whether therapy with MSCs can:
In 2018, the Lupus Foundation of America agreed to provide $3.8 million to support a Phase II clinical study of stromal cells as a potential new therapy for lupus. In the preceding Phase I clinical trial, solely funded by the LFA, investigators at the Medical University of South Carolina sought to determine if MSC therapy was safe to use in people with lupus.
Early Research Showed Promising Results
In the Phase I study, six women with refractory lupus were treated with MSCs derived from umbilical cord tissue. While some patients reported nausea, tingling and flushing, there were no serious adverse events in response to MSCs treatment. Overall, five of the six women achieved a clinically meaningful decrease in lupus disease activity scores as measured by the Systemic Lupus Erythematosus Disease Activity Index (SLEDAI), including remission in three patients. This decline in SLEDAI was sustained for over 52 weeks. Steroids were also reduced to or maintained at 10mg or less per day in five of the six patients. One patient withdrew at the eight-week visit to seek other treatment for refractory disease.
Based on these early promising results, the study transitioned to a Phase II trial.
Studying MSC Therapy in a Larger Clinical Trial
The Phase II MiSLE trial was a multicenter, randomized, double-blind, placebo-controlled study of allogeneic umbilical cord–derived MSCs in adults with active SLE whose disease had not responded adequately to standard of care (SOC) treatment. Researchers found preliminary signs that donor-derived allogeneic MSCs may benefit this group of patients.
Conducted at nine clinical centers, the study evaluated a single infusion of MSCs at one of two doses, in addition to standard care:
Of 81 participants who received an infusion, 54 received MSCs and 27 received placebo.
What Did Researchers Find?
Researchers selected a modified response index using intention to treat analysis for the study’s primary endpoint. At week 24, 38.9% of MSC recipients met the study’s primary response criteria, compared with 23.1% receiving placebo. This difference was not statistically significant (p=0.1556).
However, results in the high-dose group showed a stronger trend:
Study Safety Findings
Researchers monitored participants for 52 weeks and found no significant differences in safety outcomes between the treatment groups. No serious adverse events (SAEs) were attributed to the investigational cell therapy in any of the 81 patients.
What’s Next?
The study’s findings provide evidence that MSCs are a promising new treatment option with minimal to no side effects and the most encouraging treatment responses observed in the high-dose group using the per protocol analysis.
A proposed next step is a confirmatory trial evaluating the higher dose of 5 million cells/kg, and possible repeat dosing to assess whether long term responses can be sustained.
Watch the video to learn more.
Learn more about our lupus registry, RAY, and how you can be a part of lupus research.
There are multiple chapters near you. Select your preferred chapter.
Supporting lupus patients and advocates in Arizona.
Serving the District of Columbia, Maryland, and Northern Virginia.
Serving Kansas, Missouri, and Central & Southern Illinois
Serving north, central and west Texas, including Dallas/Fort Worth, San Antonio, Austin, El Paso, Lubbock, and surrounding areas
Serving Northern Illinois, Indiana, Iowa, Michigan, and Minnesota
Serving Connecticut, Massachusetts, Maine, New Hampshire, northern and central New Jersey, New York, Rhode Island, and Vermont
Serving Pennsylvania, Delaware and Southern New Jersey
Serving Houston, Beaumont, Corpus Christi, Harlingen and surrounding areas in Texas
There are multiple walks near you.
This website uses cookies to ensure you get the best experience. Learn more